###begin article-title 0
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 21 29 21 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 438 446 438 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 548 558 548 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1&#8211;10 </italic>
###xml 456 461 <span type="species:ncbi:9606">human</span>
The Ras-assocation family (RASSF) of tumour suppressor genes (TSGs) contains 10 members that encode proteins containing Ras-assocation (RA) domains. Several members of the RASSF family are frequently epigenetically inactivated in cancer, however, their role in leukaemia has remained largely uninvestigated. Also, RASSF10 is a predicted gene yet to be experimentally verified. Here we cloned, characterised and demonstrated expression of RASSF10 in normal human bone marrow. We also determined the methylation status of CpG islands associated with RASSF1-10 in a series of childhood acute lymphocytic leukaemias (ALL) and normal blood and bone marrow samples.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 41 48 41 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 52 60 52 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 145 152 145 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 218 226 218 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 284 291 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
COBRA and bisulphite sequencing revealed RASSF6 and RASSF10 were the only RASSF members with a high frequency of leukaemia-specific methylation. RASSF6 was methylated in 94% (48/51) B-ALL and 41% (12/29) T-ALL, whilst RASSF10 was methylated in 16% (8/51) B-ALL and 88% (23/26) T-ALL. RASSF6 and RASSF10 expression inversely correlated with methylation which was restored by treatment with 5-aza-2'deoxycytidine (5azaDC).
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 165 172 165 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 256 263 256 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 267 275 267 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 434 442 434 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
This study shows the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and represents the first report of inactivation of RASSF6 or RASSF10 in cancer. These data show epigenetic inactivation of the candidate TSGs RASSF6 and RASSF10 is an extremely frequent event in the pathogenesis of childhood leukaemia. This study also warrants further investigation of the newly identified RASSF member RASSF10 and its potential role in leukaemia.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 517 525 517 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1&#8211;6</italic>
###xml 717 724 717 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 726 732 726 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF2</italic>
###xml 734 741 734 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF4 </italic>
###xml 745 753 745 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF5A </italic>
###xml 882 883 882 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 884 885 884 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1063 1064 1063 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1065 1066 1065 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1174 1181 1174 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7 </italic>
###xml 1219 1226 1219 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 1241 1247 1241 1247 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HOJ-1 </italic>
###xml 1250 1258 1250 1258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C12ORF2 </italic>
###xml 1276 1283 1276 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF9 </italic>
###xml 1298 1305 1298 1305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P-CIP1 </italic>
###xml 1308 1314 1308 1314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAMCI </italic>
###xml 1336 1344 1336 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1359 1369 1359 1369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LOC644943 </italic>
###xml 1807 1822 1807 1822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Xenopus laevis </italic>
###xml 1927 1951 1927 1951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila melanogaster </italic>
###xml 1978 1989 1978 1989 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 2011 2013 2011 2013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1807 1821 <span type="species:ncbi:8355">Xenopus laevis</span>
###xml 1927 1950 <span type="species:ncbi:7227">Drosophila melanogaster</span>
Mutation of the Ras superfamily of proteins, or of upstream and downstream signalling components, plays a significant role in the pathogenesis of most forms of cancer. Ras proteins interact with a wide variety of downstream effectors to regulate several signalling pathways important for normal cellular growth [1]. However, Ras proteins can also regulate apoptosis via several recently described effectors, namely the RASSF family of tumour suppressor proteins. The RASSF family consists of six 'classical' members, RASSF1-6, that contain C-terminal RA (of the RalGDS/AF-6 variety) and Sav/RASSF/Hippo (SARAH) protein interaction domains. Previously we and others had demonstrated that several RASSF members, namely RASSF1A, RASSF2, RASSF4 and RASSF5A are frequently epigenetically inactivated by promoter region CpG island hypermethylation in a broad range of solid tumour types [2,3]. These proteins can regulate apoptosis through several downstream effectors such as the mammalian Serine/Threonine kinases MST1 and MST2 and modulator of apoptosis-1 (MOAP-1) [4-9]. Very recently several additional RA domain-containing family members have been identified and designated RASSF7 (also known as HRC1 located 11p15.5), RASSF8 (also known as HOJ-1 or C12ORF2 located 12p12.1), RASSF9 (also known as P-CIP1 or PAMCI located 12q21.31) and RASSF10 (also known as LOC644943 located 11p15.2). These genes encode proteins that are divergent and structurally distinct from RASSF1-6 and contain an RA domain within their extreme N-termini but lack the SARAH domain. Accordingly, RASSF7-10 are referred to as the 'N-terminal' RASSF family to distinguish them from the 'classical' members RASSF1-6. RASSF7-10 represent an evolutionarily conserved group of proteins with orthologues of all four in the lower vertebrate Xenopus laevis and a RASSF7/8 homologue [GenBank:], a RASSF9 homologue [GenBank:] and a RASSF10 homologue [GenBank:] in Drosophila melanogaster distinct from the RASSF1-6 Drosophila homologue [GenBank:] [10].
###end p 9
###begin p 10
###xml 417 424 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 428 436 428 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 509 516 509 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 520 528 520 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
To date the role of the RASSF family in childhood leukaemia has remained uninvestigated and inactivation of the 'N-terminal' RASSF members has not been investigated in any cancer. In this report we describe investigation of the RASSF family for inactivation by promoter CpG island hypermethylation in a large series of childhood B- and T-ALL and find very frequent promoter hypermethylation and loss of expression of RASSF6 and RASSF10 in B-ALL and T-ALL respectively. These findings support the candidacy of RASSF6 and RASSF10 as TSGs involved in the pathogenesis of childhood leukaemias.
###end p 10
###begin title 11
Results
###end title 11
###begin title 12
###xml 16 23 16 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
Inactivation of RASSF6 in childhood leukaemia
###end title 12
###begin p 13
###xml 84 92 84 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1&#8211;6</italic>
###xml 248 257 248 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1&#8211;5 </italic>
###xml 293 300 293 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 488 493 488 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A, B</xref>
###xml 501 502 501 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 523 524 523 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 551 558 551 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 694 701 694 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 788 795 788 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1026 1033 1026 1033 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1083 1085 1083 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1107 1108 1107 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1140 1141 1140 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 1175 1182 1175 1182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1270 1271 1270 1271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1343 1345 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1366 1367 1366 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1432 1439 1432 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1574 1581 1574 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1600 1602 1600 1602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 1623 1624 1623 1624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1857 1859 1857 1859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 1886 1893 1886 1893 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1923 1930 1923 1930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 2045 2047 2045 2047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 2107 2114 2107 2114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF2 </italic>
###xml 2217 2219 2217 2219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2494 2501 2494 2501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1695 1700 <span type="species:ncbi:9606">human</span>
We investigated the CpG island methylation status of the 'classical' RASSF members, RASSF1-6, in a large series of childhood ALL to ascertain whether epigenetic inactivation of these genes occurs in childhood leukaemia. Surprisingly, we found that RASSF1-5 were infrequently methylated whilst RASSF6 was methylated in B-ALL (94%; 48/51), T-ALL (41%; 12/29) and 5/5 unclassified childhood leukaemias but not in normal blood or bone marrow control samples (0/8 and 0/1 respectively; figure 1A, B, table 1 and Additional file 1; figure S1-2). Given that RASSF6 epigenetic inactivation has not previously been observed in any cancer we next sought to determine the extent of methylation across the RASSF6 CpG island and determine whether methylation correlated with loss or downregulation of RASSF6 expression. Bisulphite sequencing of up to 12 individual alleles from 9 leukaemia cell lines, 6 B-ALL, 6 T-ALL, 1 pre-B-ALL, 6 normal blood and 1 normal bone marrow sample confirmed leukaemia-specific methylation across the entire RASSF6 CpG island in cell lines, B-ALL and T-ALL (figure 1C, and Additional file 1; figure S3 and Additional file 2; table S1). Whilst RT-PCR showed RASSF6 was expressed in all normal tissues analysed including bone marrow (see Additional file 1; figure S4A), and in the unmethylated leukaemia cell line U937 (figure 1D and Additional file 1; figure S4B), we observed absent or downregulated expression of RASSF6 in methylated leukaemia cell lines. Treatment of hypermethylated leukaemia cell lines with 5azaDC and TSA (Trichostatin A) reactivated RASSF6 expression (figure 1D and Additional file 1; figure S4B). Using a commercially available antibody that recognises human RASSF6 protein we also observed restoration of RASSF6 protein expression following 5azaDC and TSA treatment in protein lysates from leukaemia lines (figure 1E). Thus methylation of the RASSF6 CpG island results in loss of RASSF6 expression. As mentioned previously, several RASSF members have been shown to bind Ras proteins, including RASSF6 [11]. Previously we had also demonstrated that inactivation of RASSF2 by promoter hypermethylation inversely correlates with K-Ras mutation status in colorectal carcinomas [12]. We investigated our series of leukaemias for mutations to codons 12, 13 and 61 of both K- and N-Ras. K-Ras mutations were found in 2.2% (2/89) whilst N-Ras mutations were found in 11.2% (10/89) leukaemias. However, no association was found between Ras mutation status and RASSF6 methylation status.
###end p 13
###begin p 14
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
A summary of RASSF6 and RASSF10 promoter methylation in leukaemia and control samples.
###end p 14
###begin p 15
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>RASSF6 </italic>is hypermethylated in childhood leukaemias</bold>
###xml 51 52 51 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 51 52 51 52 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 92 99 92 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 287 290 287 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 314 315 314 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 373 374 373 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 373 374 373 374 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 417 424 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 502 509 502 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 525 533 525 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6A </italic>
###xml 548 556 548 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6B </italic>
###xml 1166 1173 1166 1173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6A</italic>
###xml 1242 1245 1242 1245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 1302 1303 1302 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 1302 1303 1302 1303 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>D</italic></bold>
###xml 1324 1331 1324 1331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1384 1391 1384 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1581 1588 1581 1588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1645 1652 1645 1652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1664 1666 1664 1666 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 1664 1666 1664 1666 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 1670 1671 1670 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1670 1671 1670 1671 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 1674 1681 1674 1681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1740 1746 1740 1746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1805 1806 1805 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E</italic>
###xml 1805 1806 1805 1806 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>E</italic></bold>
###xml 1923 1928 <span type="species:ncbi:9606">human</span>
RASSF6 is hypermethylated in childhood leukaemias. A, COBRA analysis showing methylation of RASSF6 in leukaemia cell lines. No methylation was observed in normal blood or bone marrow (BM). The methylation index (MI) for each is shown below the gel image. U = undigested PCR product; T = TaqI digested PCR product. B, COBRA analysis of B-ALL and T-ALL childhood leukaemias. C, Cloning and bisulphite sequencing of the RASSF6 CpG island. Top left shows a schematic of the region analysed relative to the RASSF6 gene. Exon 1 of RASSF6A [GenBank:] and RASSF6B [GenBank:] is shown relative to the CpG island region (hatched bar), the region amplified by COBRA PCR (black bar) and the location of COBRA primers (F, FN and R). The remaining 5 panels show representative data from primary B-ALL and T-ALL leukaemias 27 and 6 respectively with leukaemia cell lines CEM, U937 and THP-1. Each horizontal line represents an individual allele whilst the circles represent single CpG dinucleotides. Filled circle represents a methylated CpG dinucleotide whereas an open circle represents an unmethylated CpG dinucleotide. Indicated by the arrow is the transcription start site of RASSF6A. The dashed vertical line indicates the CpG dinucleotide within the TaqI restriction site (TCGA) used to assay for methylation. D, Methylation of the RASSF6 CpG island correlates with loss or downregulation of RASSF6 expression. Methylated cell lines CEM, THP-1 and the unmethylated cell line U937 were cultured in the presence or absence of 5azaDC and TSA. RT-PCR analysis showed loss or downregulation of RASSF6 expression correlates with the methylation status of the RASSF6 CpG island (A and C). RASSF6 expression is restored following 5azaDC and TSA treatment. GAPDH was used as a control for RNA integrity and equal loading. E, RASSF6 protein expression is lost or downregulated in methylated leukaemia cell lines. We used an antibody towards human RASSF6 protein to investigate expression before and after 5azaDC and TSA treatment. alpha-Tubulin was used as a control for equal loading.
###end p 15
###begin title 16
###xml 30 38 30 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterisation of the human RASSF10 gene
###end title 16
###begin p 17
###xml 10 18 10 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 65 79 65 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF9/P-CIP1 </italic>
###xml 338 346 338 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 681 689 681 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 948 949 948 949 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 951 954 951 954 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ATG</bold>
###xml 954 955 954 955 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 1071 1074 1071 1074 <underline xmlns:xlink="http://www.w3.org/1999/xlink">A/G</underline>
###xml 1076 1079 1076 1079 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ATG</bold>
###xml 1079 1080 1079 1080 <underline xmlns:xlink="http://www.w3.org/1999/xlink">G</underline>
###xml 1175 1177 1175 1177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1178 1180 1178 1180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1337 1345 1337 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1370 1378 1370 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1554 1562 1554 1562 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1621 1629 1621 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1643 1649 1643 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNaseI</italic>
###xml 1708 1710 1708 1710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1757 1764 1757 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10</italic>
###xml 1890 1892 1890 1892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 2252 2260 2252 2260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 2631 2633 2631 2633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 2638 2640 2638 2640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2D</xref>
###xml 2810 2818 2810 2818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 2895 2903 2895 2903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 473 478 <span type="species:ncbi:9606">human</span>
###xml 1665 1670 <span type="species:ncbi:9606">human</span>
###xml 2609 2614 <span type="species:ncbi:9606">human</span>
###xml 2670 2676 <span type="species:ncbi:10090">murine</span>
###xml 2804 2809 <span type="species:ncbi:9606">human</span>
###xml 3094 3099 <span type="species:ncbi:9606">human</span>
The human RASSF10 gene has been predicted based on homology with RASSF9/P-CIP1 but has yet to be supported by experimental evidence. UCSC  and Ensembl  human genome browsers predict a 615 amino acid protein encoded by a two exon gene separated by a short intron of 104 bp. Interestingly, no 5' or 3'UTRs were predicted, hence we reasoned RASSF10 had not been completely characterised. Sequencing of the only IMAGE clone available [IMAGE:4413366] [GenBank:] obtained from a human liver cDNA library revealed a 3'UTR of 478 bp beyond the predicted stop codon followed by a poly A-tail. Contrary to the UCSC and Ensembl genome browsers however, the IMAGE clone sequence suggested the RASSF10 gene did not contain introns and predicted alternative transcription and translation initiation sites located Chr11:12,987,466 and Chr11:12,987,700 respectively (UCSC genome browser, March 2006 freeze). Analysis of the sequence flanking this alternative ATG (GCCATGG) support its candidacy as a genuine translation initiation site since it matches the consensus 'Kozak' sequence of A/GCCATGG in which the important -3 and +4 A/G and G residues respectively (underlined) were conserved [13,14]. Furthermore, translation initiation site prediction software at  also predicted the ATG at Chr11:12,987,700 is the translation initiation site within the RASSF10 gene. This suggested the RASSF10 gene contains a shorter open reading frame encoding a 507 amino acid protein. However, since the IMAGE clone may be incomplete we confirmed the transcription start site of the RASSF10 gene using 5'RACE. We first demonstrated expression of the RASSF10 transcript in DNaseI-treated normal human bone marrow RNA using RT-PCR (figure 2A). This RNA was then subjected to 5'RACE using RASSF10-specific antisense primers, which generated a major product of ~330 bp and several larger and smaller minor products (figure 2B). These products were gel purified, cloned and sequenced to reveal a transcription start site located at Chr11:12,987,444 (UCSC genome browser, March 2006 freeze) with two alternative transcription start sites at +119 bp and +169 bp (Chr11:12,987,565 and Chr11:12,987,613, respectively). This revealed the presence of a 5'UTR of up to 431 bp and confirms the RASSF10 gene likely encodes a much shorter 507 amino acid protein. That the predicted N-terminal 108 amino acids may not actually be part of the RASSF10 protein is supported by ClustalW alignments of RASSF7-10. These alignments show the predicted N-terminal 108 amino acids are extremely divergent with no significant homology to RASSF7-9 or with any other human protein (figure 2C and 2D). Interestingly, the Rassf10 murine protein [Genbank:] also lacks this divergent N-terminus and is 508 amino acids in length. Therefore, we have characterised the human RASSF10 gene and verified expression in normal bone marrow. We provide evidence that RASSF10 is a single exon gene with a 5'UTR of up to 431 bp, a 3'UTR of 478 bp and an open reading frame encoding a protein of 507 amino acids, not 615 amino acids as predicted by current versions of human genome browsers.
###end p 17
###begin p 18
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterisation of the <italic>RASSF10 </italic>gene</bold>
###xml 38 39 38 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 38 39 38 39 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 79 87 79 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 116 117 116 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 116 117 116 117 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 140 148 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 360 368 360 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 374 375 374 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 374 375 374 375 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 420 428 420 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 533 543 533 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 627 628 627 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">D</italic>
###xml 627 628 627 628 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>D</italic></bold>
###xml 691 701 691 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 185 190 <span type="species:ncbi:9606">human</span>
Characterisation of the RASSF10 gene. A, RT-PCR analysis showing expression of RASSF10 in normal human bone marrow. B, The 5' region of the RASSF10 transcript was amplified from normal human bone marrow using 5'RACE. Arrowed is the major product of 5'RACE which was cloned and sequenced to determine the transcription start point and open reading frame of the RASSF10 gene. C, Schematic summarising the structure of the RASSF10 gene and the open reading frame encoding a shortened protein of 507amino acids that does not contain the in silico predicted N-terminal 108 amino acids that are divergent from the RASSF7-9 proteins. D, ClustalW alignments of RASSF7-10 proteins including both the in silico predicted 615 amino acid RASSF10 [GenBank:] and the shorter 507 amino acid RASSF10 confirmed in this study suggesting the divergent N-terminal 108 amino acids is not likely to be part of the RASSF10 protein.
###end p 18
###begin title 19
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
Inactivation of RASSF10 in childhood leukaemia
###end title 19
###begin p 20
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 98 106 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 143 151 143 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 259 267 259 267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 346 354 346 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 527 535 527 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 573 581 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 727 728 727 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 767 775 767 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 922 930 922 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1042 1050 1042 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1094 1102 1094 1102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1235 1237 1235 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 1265 1273 1265 1273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
RASSF10 contains a large CpG island that covers the majority of the gene. Given the expression of RASSF10 in bone marrow we questioned whether RASSF10 is also inactivated by promoter methylation in the same series of childhood leukaemias. We investigated the RASSF10 CpG island for DNA hypermethylation using COBRA and bisulphite sequencing. The RASSF10 CpG island was heavily methylated in 7/7 leukaemia cell lines (figure 3A). Next, we investigated childhood B- and T-ALL, normal blood and normal bone marrow for evidence of RASSF10 CpG island hypermethylation. We found RASSF10 was methylated in 23/26 (88%) T-ALL and 8/51 (16%) B-ALL but was unmethylated in normal bone marrow and 21 normal blood samples (figure 3A, table 1). Direct bisulphite sequencing of the RASSF10 CpG island confirmed the presence of dense methylation across the entire region analysed (figure 3B). To investigate the effects of methylation on RASSF10 expression we analysed the leukaemia cell lines THP-1 and SUP-T1 using RT-PCR. We found low level expression of RASSF10 in THP-1 (partially methylated) and loss of RASSF10 expression in SUP-T1 (completely methylated) and in both cases expression was upregulated following 5azaDC and TSA treatment (figure 3C). Thus, methylation of the RASSF10 CpG island inactivates expression of the gene very frequently in T-ALL and in a subset of B-ALL.
###end p 20
###begin p 21
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>RASSF10 </italic>is hypermethylated in childhood leukaemias</bold>
###xml 52 53 52 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 52 53 52 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 100 108 100 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 300 303 300 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 331 335 331 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BstU</italic>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 359 360 359 360 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 566 574 566 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1021 1024 1021 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 1037 1040 1037 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bst</italic>
###xml 1099 1100 1099 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1099 1100 1099 1100 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>C</italic></bold>
###xml 1121 1129 1121 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1182 1190 1182 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1399 1407 1399 1407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1464 1472 1464 1472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1484 1486 1484 1486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 1484 1486 1484 1486 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A </italic></bold>
###xml 1490 1491 1490 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1490 1491 1490 1491 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 1494 1502 1494 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1561 1567 1561 1567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
RASSF10 is hypermethylated in childhood leukaemias. A, COBRA analysis showing methylation status of RASSF10 in leukaemia cell lines and normal bone marrow, normal blood, primary T-ALL and primary B-ALL. No methylation was observed in normal blood or bone marrow (BM). U = undigested PCR product; T = TaqI digested PCR product. B = BstUI digested PCR product. B, Direct bisulphite sequencing of normal blood, normal bone marrow, leukaemia cell lines and primary T-ALL leukaemias. Top shows a schematic of the region amplified by COBRA PCR (black bar) relative to the RASSF10 gene and CpG island region (hatched bar). Each horizontal line represents the total DNA amplified from the sample whilst the circles represent single CpG dinucleotides. Filled black circle represents a completely methylated CpG dinucleotide, open circle represents a completely unmethylated CpG dinucleotide and filled gray circle represents a partially methylated CpG dinucleotide. The dashed vertical line indicates the CpG dinucleotides within TaqI (TCGA) and BstUI (CGCG) restriction sites used to assay for methylation. C, Methylation of the RASSF10 CpG island correlates with loss or downregulation of RASSF10 expression. The partially methylated cell line THP-1 and the completely methylated cell line SUP-T1 were cultured in the presence or absence of 5azaDC and TSA. RT-PCR analysis showed loss or downregulation of RASSF10 expression correlates with the methylation status of the RASSF10 CpG island (A and B). RASSF10 expression is restored following 5azaDC and TSA treatment. GAPDH was used as a control for RNA integrity and equal loading. Ct = control mock treated; RT = reverse transcriptase.
###end p 21
###begin p 22
###xml 137 144 137 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7 </italic>
###xml 148 155 148 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 221 228 221 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF9 </italic>
###xml 309 316 309 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7 </italic>
###xml 377 384 377 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 607 614 607 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 649 656 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 739 740 739 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Next, we investigated the remaining 'N-terminal' RASSF members to determine whether they too become inactivated in childhood leukaemias. RASSF7 and RASSF8 both contain 5' CpG islands encompassing their first exon, whilst RASSF9 does not contain a CpG island. As determined by COBRA and bisulphite sequencing, RASSF7 was unmethylated in all leukaemia cell lines analysed (0/5). RASSF8 methylation was found to be infrequent, occurring in 2/6 leukaemia cell lines, 2/19 (10%) childhood T-ALLs, and 4/46 (9%) B-ALL with no methylation detectable in normal bone marrow or normal blood (0/7). Methylation of the RASSF8 CpG island correlated with loss of RASSF8 expression which was restored following treatment with 5azaDC (and Additional file 1; figure S5).
###end p 22
###begin title 23
Discussion
###end title 23
###begin p 24
###xml 94 95 94 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 96 97 96 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 127 133 127 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1</italic>
###xml 134 136 134 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6 </italic>
###xml 205 211 205 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1</italic>
###xml 212 214 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5 </italic>
###xml 328 335 328 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 476 483 476 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 564 565 564 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 568 575 568 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 666 673 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 722 729 722 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 804 806 804 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 845 852 845 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 909 915 909 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6</italic>
###xml 988 990 988 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1033 1040 1033 1040 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1097 1103 1097 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6</italic>
###xml 1208 1210 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1219 1226 1219 1226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1324 1326 1324 1326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1327 1329 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1489 1496 1489 1496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1591 1598 1591 1598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1628 1635 1628 1635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 1637 1645 1637 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF5A </italic>
###xml 1649 1656 1649 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
In recent years several members of the classical RASSF family have emerged as important TSGs [2,3,15]. Whether inactivation of RASSF1-6 plays a role in leukaemia has not yet been determined. We found that RASSF1-5 were not frequently methylated in our series of childhood ALL. Instead, we observed very frequent inactivation of RASSF6 reiterating the importance of several classical RASSF members in the development of different forms of cancer. Evidence is accumulating that RASSF6 plays a role in tumourigenesis and likely functions as a regulator of apoptosis [2]. RASSF6 is downregulated in 30-60% of a variety of solid tumours [11]. SiRNA-mediated knockdown of RASSF6 enhances tumourigenic growth in soft agar whilst RASSF6 overexpression reduces tumour growth in a variety of tumour cell lines [11,16]. The growth inhibitory properties of RASSF6 are most likely a result of induction of apoptosis since RASSF6-induced cell death was concomitant with a variety of apoptotic markers [11,16]. Previously, we had demonstrated that RASSF6 interacted with K-Ras in a GTP-dependent manner and that RASSF6-induced apoptosis was enhanced synergistically by co-transfection with constitutively active K-RasG12V [11]. Thus, RASSF6 can mediate the growth inhibitory properties of Ras proteins. In agreement with previous studies [17-19] the frequency of mutations to codons 12, 13 and 61 of both K- and N-Ras combined in our series of leukaemias was only 14% (12/89). Therefore, inactivation of RASSF6 may provide the alternative mechanism of Ras pathway inactivation in B-ALL. In T-ALL, in which RASSF6 methylation is less frequent, RASSF1A, RASSF5A and RASSF6 methylation may account for Ras pathway inactivation in the majority of cases.
###end p 24
###begin p 25
###xml 79 89 79 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7&#8211;10 </italic>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 95 105 95 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7&#8211;10 </italic>
###xml 310 317 310 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7 </italic>
###xml 366 373 366 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 396 403 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
The recently identified 'N-terminal' RASSFs consist of four members designated RASSF7-10 [20]. RASSF7-10 represents a structurally distinct yet evolutionarily conserved sub-group of the RASSF family. It has not yet been determined whether RASSF7-10 bind to Ras proteins. We found no evidence of methylation of RASSF7 in leukaemia cell lines. Hypermethylation of the RASSF8 CpG island and loss of RASSF8 expression was observed in 2/6 leukaemia cell lines.
###end p 25
###begin p 26
###xml 27 34 27 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 125 132 125 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 206 213 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF9 </italic>
However, since we observed RASSF8 CpG island hypermethylation in only 2/19 T-ALLs and 4/46 B-ALLs we suspect inactivation of RASSF8 may be involved in the pathogenesis of only a small subset of leukaemias. RASSF9 was not investigated for inactivation by DNA methylation due to lack of a CpG island.
###end p 26
###begin p 27
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">LOC644943 </italic>
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 74 87 74 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF9/P-CIP1</italic>
###xml 178 189 178 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Drosophila </italic>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CG32150</italic>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 352 360 352 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 408 417 408 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X.laevis </italic>
###xml 432 443 432 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M.musculus </italic>
###xml 462 470 462 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rassf10 </italic>
###xml 560 569 560 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">X.laevis </italic>
###xml 573 592 573 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M.musculus Rassf10 </italic>
###xml 638 646 638 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 714 721 714 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10</italic>
###xml 755 763 755 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 847 855 847 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1042 1052 1042 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in silico </italic>
###xml 1268 1276 1268 1276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1468 1476 1468 1476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1524 1532 1524 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1579 1587 1579 1587 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1689 1696 1689 1696 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1747 1755 1747 1755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 2058 2065 2058 2065 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 2068 2076 2068 2076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 119 125 <span type="species:ncbi:9606">humans</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 408 416 <span type="species:ncbi:8355">X.laevis</span>
###xml 432 442 <span type="species:ncbi:10090">M.musculus</span>
###xml 455 461 <span type="species:ncbi:10090">Murine</span>
###xml 560 568 <span type="species:ncbi:8355">X.laevis</span>
###xml 573 583 <span type="species:ncbi:10090">M.musculus</span>
###xml 632 637 <span type="species:ncbi:9606">human</span>
###xml 749 754 <span type="species:ncbi:9606">human</span>
###xml 820 825 <span type="species:ncbi:9606">human</span>
###xml 1003 1008 <span type="species:ncbi:9606">human</span>
LOC644943 was very recently designated RASSF10 based on its homology with RASSF9/P-CIP1. The existence of this gene in humans has yet to be experimentally verified. However, the Drosophila homologue, CG32150, is expressed in several sensory organ precursors and seems to be required for correct Hedgehog pathway signaling [21,22]. Orthologues of human RASSF10 can be found in several model species including X.laevis [GenBank:] and M.musculus [GenBank:]. Murine Rassf10 is expressed in several tissues including salivary gland, testes, kidney, lung and brain. X.laevis and M.musculus Rassf10 proteins share 60 and 85% identity with human RASSF10 respectively. To date there has been no investigation of vertebrate RASSF10. Here we characterized the human RASSF10 gene and transcript and demonstrate expression in normal human bone marrow. Whether RASSF10 is expressed in other tissues was not determined in the present study, though this is likely since we obtained an IMAGE clone derived from a normal human liver cDNA library. Furthermore, in silico sources (Unigene [Hs.693473] and Genecards) provide further evidence of expression in brain, skeletal muscle, pancreas, liver and trachea. Interestingly, we demonstrate that current genome browser predictions of the RASSF10 gene and protein may require revision and provide evidence of alternative transcription and translation inititation sites that produce a much shorter protein of 507 amino acids. We also found RASSF10 was very frequently inactivated in T-ALL (88%). RASSF10 CpG island methylation correlated with loss of RASSF10 expression which was restored following 5azaDC and TSA treatment. It is particularly interesting that RASSF6 methylation occurs very frequently in B-ALL whilst RASSF10 methylation is more restricted to T-ALL. It is unclear at present whether this represents independent routes to inactivation of the same pathway or whether it reflects inactivation of separate pathways important in the development of these different subtypes of leukaemia. Nevertheless, inactivation of RASSF6 or RASSF10 by promoter DNA hypermethylation appears to be an event associated with the majority of childhood leukaemias.
###end p 27
###begin title 28
Conclusion
###end title 28
###begin p 29
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 252 259 252 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 519 527 519 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
In summary, we show that the hypermethylation profile of RASSF genes in leukaemias is distinct from that of solid tumours and show for the first time that RASSF6 is also inactivated in cancer, but specifically in leukaemias. Given the emerging role of RASSF6 as a Ras effector and possible TSG involved in the regulation of apoptosis it is likely that loss of expression may be involved in the ability of leukaemic cells to evade apoptosis. Our data also suggests that of the newly identified 'N-terminal' RASSF genes, RASSF10 is an interesting candidate for further analysis in other types of cancer and for functional investigation to ascertain its role in leukaemias.
###end p 29
###begin title 30
Methods
###end title 30
###begin title 31
Tumour samples
###end title 31
###begin p 32
###xml 463 471 <span type="species:ncbi:9606">patients</span>
Twelve leukaemia cell lines (DND-41, CCRF-CEM (CEM), U937, Jurkat (JKT), TALL-1, NALM1, NALM6, NALM16, NALM17, THP-1, SUP-T1 and MOLT-4) and 89 primary childhood ALL comprising 51 B-cell ALL (B-ALL), 32 T-cell ALL (T-ALL), 1 pre-B-ALL and 5 unclassified leukaemias were analysed. In addition a total of 21 normal blood samples and 1 normal bone marrow (BM, AMS Biotechnology) sample were used as controls. All DNA samples were obtained with informed consent from patients and family members.
###end p 32
###begin title 33
Methylation analysis
###end title 33
###begin p 34
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 99 107 99 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 111 118 111 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF2 </italic>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF3</italic>
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF4 </italic>
###xml 219 227 219 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF5A </italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 327 329 327 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 339 344 339 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6</italic>
###xml 477 485 477 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6A </italic>
###xml 501 509 501 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6B </italic>
###xml 604 605 604 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 665 671 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7</italic>
###xml 673 680 673 680 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 684 692 684 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 755 762 755 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF7 </italic>
###xml 766 773 766 773 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 859 867 859 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1065 1070 1065 1070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TaqI </italic>
###xml 1125 1131 1119 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">BstUI </italic>
###xml 1277 1283 1265 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6</italic>
###xml 1385 1392 1373 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 1396 1403 1384 1391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10</italic>
###xml 1472 1479 1460 1467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
Bisulphite modification was performed as described previously [23]. Promoter methylation status of RASSF1A and RASSF2 were determined using MSP as described previously [12]. The methylation status of RASSF3, RASSF4 and RASSF5A were determined by combined bisulphite restriction analysis (COBRA) as described in Hesson et al., [12], Hesson et al., [23] and Eckfeld et al., [24]. For RASSF6, primers were designed to amplify the entire CpG island encompassing the first exons of RASSF6A (NM_177532) and RASSF6B (NM_201431) from bisulphite modified DNA using semi-nested bisulphite PCR (see additional file 2; table S2 for primer sequences). The methylation status of RASSF7, RASSF8 and RASSF10 were determined by COBRA and direct bisulphite sequencing. For RASSF7 and RASSF8 primers were designed to amplify a portion of the CpG island encompassing exon 1. The RASSF10 CpG island covers the majority of the gene. We designed primers to amplify a portion of the CpG island encompassing the 5' region of the gene. Five microlitres of PCR product was incubated with 2 U TaqI restriction enzyme (TCGA) for 2 h at 65degreesC or 2 U BstUI restriction enzyme (CGCG) for 2 h at 60degreesC before visualisation on a 2% agarose gel. Samples selected for bisulphite sequencing were cloned (RASSF6) into the CloneJET vector (Fermentas) according to manufacturers instructions or sequenced directly (RASSF8 and RASSF10). Up to 12 individual colonies were chosen for colony PCR using the RASSF6 COBRA primers. Products were then sequenced to ascertain the methylation status of individual alleles and to determine the methylation index (MI). The MI was calculated as a percentage using the equation; number of CpG dinucleotides methylated/total number of CpG dinucleotides sequenced x 100.
###end p 34
###begin title 35
Cell lines, 5azaDC treatment and RT-PCR
###end title 35
###begin p 36
###xml 186 187 180 181 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 288 289 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 659 666 649 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 729 731 719 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A </italic>
###xml 735 737 725 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B </italic>
###xml 841 849 831 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 940 948 930 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 979 986 969 976 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNaseI </italic>
###xml 1190 1197 1180 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 1297 1303 1287 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 1363 1365 1353 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1368 1383 1358 1373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6, RASSF8 </italic>
###xml 1387 1395 1377 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 1465 1466 1454 1455 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1501 1505 1490 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 473 476 <span type="species:ncbi:7460">bee</span>
Leukaemia cell lines were maintained in RPMI1640 (Sigma) supplemented with 10% FCS, 2 mM Glutamine, 20 mM HEPES, 1 mM Sodium Pyruvate and 12.6 mM Glucose Monohydrate at 37degreesC, 5% CO2. Cells were treated with 5 muM of the DNA demethylating agent 5azaDC (Sigma) freshly prepared in ddH2O and filter-sterilised. The medium (including 5 muM 5azaDC) was changed every day for 5 days. Cells were also treated on day 4 with 0.1 muM TSA for 24 hrs. RNA was prepared using RNA bee (AMS biotechnology) according to manufacturers' instructions. cDNA was generated from 1 mug total RNA using SuperScript III (Invitrogen) and polyN primers. We analysed expression of RASSF6 using primers specific for exons 2 and 4 that amplify both the A and B isoforms (F = 5'-ATGATGGCTCACCAGTACCC-3' and R = 5'-GGTCGTTTTACTCCCCAGAA-3'). We analysed expression of RASSF10 using the primers 5'-CCATGACCCAGGAGAAACAG-3' (F) and 5'-TGCTGGCGAATTGTGTGGTC-3' (R). Since RASSF10 is a single exon gene we first DNaseI (Fermentas) treated all RNA samples prior to cDNA synthesis and included control experiments in which reverse transcriptase was omitted (No RT controls) in all samples analysed. We analysed expression of RASSF8 using the primers F = 5'-TCCATTGAGAAACAGCTGGA-3' and R = 5'-TGGCACAAATCAAAAAGGAA-3'. In all cases a GAPDH control was included using conditions described previously [12]. RASSF6, RASSF8 and RASSF10 were amplified from 50 ng cDNA using 0.8 muM of each primer, 3 mM MgCl2, 0.25 mM dNTPs and 1 U Fast start Taq (Roche).
###end p 36
###begin title 37
Protein expression
###end title 37
###begin p 38
###xml 459 465 <span type="species:ncbi:9986">rabbit</span>
Leukaemia lines THP-1 and CEM were treated with 5azaDC as above. Protein extracts were then prepared by lysis in 50 mM TrisHCl pH7.5, 1 mM EDTA, 1 mM EGTA, 50 mM Sodium Fluoride, 5 mM Sodium Pyrophosphate, 1 mM Sodium Orthovanadate, 0.27 M Sucrose, 1% Triton and protease inhibitor cocktail (Roche). Twenty micrograms of protein extracts were resolved by SDS-PAGE, transferred to PVDF membrane and probed for the presence of RASSF6 using 1 mug/mL anti-RASSF6 rabbit-raised polyclonal antibody (ProteinTech Group).
###end p 38
###begin title 39
5' Rapid Amplification of cDNA Ends (RACE)
###end title 39
###begin p 40
###xml 68 75 68 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DNaseI </italic>
###xml 181 184 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">nd </sup>
###xml 211 219 211 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 282 290 282 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 357 364 357 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10</italic>
###xml 698 703 <span type="species:ncbi:9606">human</span>
One microgram of total RNA from bone marrow (AMS Biotechnology) was DNaseI (Fermentas) treated according to manufacturers instructions. We synthesised cDNA using a 5'/3' RACE kit (2nd generation, Roche) and the RASSF10 antisense primer 5'-TGCTGGCGAATTGTGTGGTC-3'. The 5' UTR of the RASSF10 transcript was obtained using nested PCR with the nested antisense RASSF10-specific primers 5'-GCTGTTTCTCCTGGGTCATG-3' and 5'-TATCTTCTTTTCCGAAGGATCCATG-3' used in combination with a polyT-anchor primer. Control experiments in which reverse transcriptase was omitted were also performed to eliminate DNA contamination. PCR products were gel extracted, sequenced and the sequences obtained aligned against the human genome browser.
###end p 40
###begin title 41
Mutation analysis
###end title 41
###begin p 42
PCR primers were used to amplify exons 2 and 3 of the K- and N-Ras genes from genomic DNA. The primers were as follows: K-Ras exon 2 F 5'-TTTGTATTAAAAGGTACTGGTGGAG-3'; K-Ras exon 2 R 5'-CCTTTATCTGTATCAAAGAATGGTC-3'; K-Ras exon 3 F 5'-CTGTGTTTCTCCCTTCTCAGG-3'; K-Ras exon 3 R 5'-AGAAAGCCCTCCCCAGTCCT-3'; N-Ras exon 2 F 5'-GATGTGGCTCGCCAATTAAC-3'; N-Ras exon 2 R 5'-GAATATGGGTAAAGATGATCCGAC-3'; N-Ras exon 3 F 5'-GTTAGATGCTTATTTAACCTTGGC-3'; N-Ras exon 3 R 5'-TGTGGTAACCTCATTTCCCC-3'. PCR products were directly sequenced using ABI BigDye cycle sequencing kit (Perkin-Elmer).
###end p 42
###begin title 43
Abbreviations
###end title 43
###begin p 44
RASSF: Ras-association family; TSG: tumour suppressor gene; RA: Ras-association domain; ALL: Acute Lymphocytic Leukaemia; 5azaDC: 5-aza-2'deoxycytidine; TSA: Trichostatin A; SARAH: Sav/RASSF/Hpo domain; MSP: Methylation-specific PCR; COBRA: Combined Bisulphite Restriction Analysis; RACE: Rapid Amplification of cDNA Ends.
###end p 44
###begin title 45
Competing interests
###end title 45
###begin p 46
The authors declare that they have no competing interests.
###end p 46
###begin title 47
Authors' contributions
###end title 47
###begin p 48
LBH acquired the majority of data (involving tissue culture, assay design, molecular genetic studies, bioinformatics and protein analysis), wrote the manuscript and contributed to the design and concept of the study. TLD performed bisulphite modification and contributed to COBRA analysis and mutation screening. WNC performed COBRA, bisulphite sequencing and expression analysis pertaining to RASSF8. DC, MG, RC and ATB provided leukaemia DNA samples and cell lines. ADC and ERM contributed to the concept of the study. FL conceived the studies, oversaw the experimental work and helped draft the manuscript and established all the collaborations. All authors have read and approved the final manuscript.
###end p 48
###begin title 49
Supplementary Material
###end title 49
###begin title 50
Additional file 1
###end title 50
###begin p 51
###xml 0 25 0 25 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RASSF methylation profile</bold>
###xml 113 120 113 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 124 132 124 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF10 </italic>
###xml 156 216 156 216 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Figure S1: RASSF methylation profile of leukaemia cell lines</bold>
###xml 244 252 244 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 256 263 256 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF2 </italic>
###xml 322 328 322 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF3</italic>
###xml 329 331 329 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">6 </italic>
###xml 360 367 360 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A</italic>
###xml 369 377 369 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF5A </italic>
###xml 381 388 381 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 441 448 441 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF2 </italic>
###xml 452 459 452 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF3 </italic>
###xml 494 501 494 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF4 </italic>
###xml 687 690 687 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 714 772 714 772 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Figure S2: RASSF methylation profile of primary leukaemias</bold>
###xml 912 920 912 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF1A </italic>
###xml 924 932 924 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF5A </italic>
###xml 1000 1007 1000 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF4 </italic>
###xml 1115 1122 1115 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF4 </italic>
###xml 1187 1194 1187 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1437 1440 1437 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 1504 1511 1504 1511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1464 1521 1464 1521 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Figure S3: Bisulphite sequencing of the <italic>RASSF6 </italic>CpG island</bold>
###xml 1536 1538 1536 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1716 1723 1716 1723 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1705 1776 1705 1776 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Figure S4: <italic>RASSF6 </italic>expression in normal tissues and leukaemia cell lines</bold>
###xml 1778 1779 1778 1779 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1778 1779 1778 1779 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 1781 1788 1781 1788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1831 1832 1831 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 1831 1832 1831 1832 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 1849 1856 1849 1856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 1994 2000 1994 2000 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GAPDH </italic>
###xml 2071 2078 2071 2078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 2114 2121 2114 2121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 2041 2134 2041 2134 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Figure S5: Methylation of the <italic>RASSF8 </italic>CpG island infrequently inactivates <italic>RASSF8 </italic>in leukaemias</bold>
###xml 2136 2137 2136 2137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 2136 2137 2136 2137 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>A</italic></bold>
###xml 2171 2178 2171 2178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 2417 2418 2417 2418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 2417 2418 2417 2418 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>B</italic></bold>
###xml 2439 2446 2439 2446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
###xml 2499 2506 2499 2506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF8 </italic>
RASSF methylation profile. The data provided represent analysis of RASSF members and additional data relating to RASSF6 and RASSF10 in childhood leukaemia. Figure S1: RASSF methylation profile of leukaemia cell lines. The methylation status of RASSF1A and RASSF2 was determined using MSP whereas the methylation status of RASSF3-6 were determined using COBRA. RASSF1A, RASSF5A and RASSF6 were hypermethylated in leukaemia cell lines whereas RASSF2 and RASSF3 showed no evidence of methylation. RASSF4 was methylated in both leukaemia cell lines and normal blood. For MSP assays M = methylated specific PCR; U = unmethylated specific PCR. For COBRA assays U = undigested PCR product; T = TaqI digested PCR product. Figure S2: RASSF methylation profile of primary leukaemias. RASSF genes showing evidence of hypermethylation in leukaemia cell lines were investigated for methylation in B-ALL and T-ALL leukaemias. RASSF1A and RASSF5A were infrequently methylated in T-ALL (2/12 and 2/24 respectively). RASSF4 was methylated in 25/25 T-ALL but in only 7/50 B-ALL leukaemias, however given the low level methylation of RASSF4 observed in normal blood this gene was not investigated further. RASSF6 was methylated in 48/51 (94%) B-ALL and 12/29 (41%) T-ALL but not in normal bone marrow (BM) or blood control samples. For MSP assays M = methylated specific PCR; U = unmethylated specific PCR. For COBRA assays U = undigested PCR product; T = TaqI digested PCR product. Figure S3: Bisulphite sequencing of the RASSF6 CpG island. As in figure 1C up to 12 alleles from B-ALL, T-ALL leukaemia cell lines, normal blood and normal bone marrow were cloned and sequenced. The methylation index (MI) is given for each. Figure S4: RASSF6 expression in normal tissues and leukaemia cell lines. A, RASSF6 mRNA was detected in all tissues analysed. B, Restoration of RASSF6 mRNA expression in methylated leukaemia cell lines following treatment with 5azaDC and TSA showing the additional cell lines JKT and REH. GAPDH was used as a control for equal loading. Figure S5: Methylation of the RASSF8 CpG island infrequently inactivates RASSF8 in leukaemias. A, Direct bisulphite sequencing of RASSF8 CpG island PCR products. Filled black circle represents a completely methylated CpG dinucleotide, open circle represents a completely unmethylated CpG dinucleotide and filled gray circle represents a partially methylated CpG dinucleotide. B, Methylation of the RASSF8 CpG island correlates with loss or downregulation of RASSF8 expression which is restored following 5azaDC treatment.
###end p 51
###begin p 52
Click here for file
###end p 52
###begin title 53
Additional file 2
###end title 53
###begin p 54
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 methylation indexes and PCR primers used within this study</bold>
###xml 246 256 246 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table S1: </bold>
###xml 298 305 298 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RASSF6 </italic>
###xml 404 414 404 414 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Table S2: </bold>
RASSF6 methylation indexes and PCR primers used within this study. The data provided summarise RASSF6 methylation index data in cell lines, primary tumour and control samples (Table S1). PCR primers used in this study are also listed (Table S2). Table S1: A summary of the methylation index of the RASSF6 CpG island in leukaemia cell lines, B-ALL, T-ALL and normal blood and bone marrow control samples. Table S2: MSP and COBRA primer sequences used within this study.
###end p 54
###begin p 55
Click here for file
###end p 55
###begin title 56
Acknowledgements
###end title 56
###begin p 57
FL is funded in part by SPARKS (Sport Aiding Medical Research For Kids) and CRUK.
###end p 57
###begin article-title 58
Targeting RAS signalling pathways in cancer therapy
###end article-title 58
###begin article-title 59
###xml 68 73 <span type="species:ncbi:9606">human</span>
The Ras-association domain family (RASSF) members and their role in human tumourigenesis
###end article-title 59
###begin article-title 60
The role of RASSF1A methylation in cancer
###end article-title 60
###begin article-title 61
Identification of a novel Ras-regulated proapoptotic pathway
###end article-title 61
###begin article-title 62
Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras
###end article-title 62
###begin article-title 63
The RASSF1A tumor suppressor activates Bax via MOAP-1
###end article-title 63
###begin article-title 64
The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death
###end article-title 64
###begin article-title 65
RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein
###end article-title 65
###begin article-title 66
Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1
###end article-title 66
###begin article-title 67
RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis
###end article-title 67
###begin article-title 68
RASSF6 is a novel member of the RASSF family of tumor suppressors
###end article-title 68
###begin article-title 69
CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations
###end article-title 69
###begin article-title 70
Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes
###end article-title 70
###begin article-title 71
Interpreting cDNA sequences: some insights from studies on translation
###end article-title 71
###begin article-title 72
###xml 69 74 <span type="species:ncbi:9606">human</span>
Role of the Ras-association domain family 1 tumor suppressor gene in human cancers
###end article-title 72
###begin article-title 73
Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways
###end article-title 73
###begin article-title 74
RAS mutation is associated with hyperdiploidy and parental characteristics in pediatric acute lymphoblastic leukemia
###end article-title 74
###begin article-title 75
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia
###end article-title 75
###begin article-title 76
K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements
###end article-title 76
###begin article-title 77
The RASSF proteins in cancer; from epigenetic silencing to functional characterization
###end article-title 77
###begin article-title 78
Genetic programs activated by proneural proteins in the developing Drosophila PNS
###end article-title 78
###begin article-title 79
###xml 41 64 <span type="species:ncbi:7227">Drosophila melanogaster</span>
A genome-wide RNA interference screen in Drosophila melanogaster cells for new components of the Hh signaling pathway
###end article-title 79
###begin article-title 80
Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas
###end article-title 80
###begin article-title 81
RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family
###end article-title 81

